Aim To analyse the peripheral extent of choroidal circulation using ultra-widefield (UWF) indocyanine green angiography (ICGA) in healthy eyes.
Methods UWF ICGA images of 55 eyes of 36 healthy subjects were captured using the Optos California (Optos, Dunfermline, United Kingdom) in this prospective observational study. Images were analysed to locate the peripheral extent of the visible choroidal circulation, and the boundary was marked in ImageJ (v1.52). Each pixel annotated as the border of the choroidal circulation was projected individually to its anatomically correct location on the three-dimensional model eye, and spherical trigonometry was applied (using the Optos software) to calculate its respective radial distance from the centre of the optic disc in metric units (corrected by stereographic projection) for each quadrant.
Results The mean area of the peripheral extent was estimated to be 893.2 mm2 (95% CI: 844.2 to 942.3 mm2). The mean distance (range) of this boundary from optic nerve centre was 18.22 mm (95% CI: 14.0 to 23.14 mm). Multiple regression analysis with age, gender, axial length or ethnicity showed no relationship. There was excellent inter-grader reproducibility, with intraclass correlation coefficients of 0.95 (95% CI: 0.80 to 0.99, p<0.001) for distance and 0.99 (95% CI: 0.988 to 0.999, p<0.001) for area measurements.
Conclusions The peripheral choroidal boundary may be defined using UWF ICGA. Knowledge of the normal extent and its variability is essential to understand the impact of disease on the choroidal vasculature.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
A portion of this manuscript was presented as a poster in ARVO 2019.
Twitter Michael Singer.
Contributors All the authors have contributed equally and substantially to the following: conception or design of the work, the acquisition, analysis and interpretation of data; drafting the work and revisions required; final approval of the version published.
Funding Funding for this clinical study was provided by Optos. No conflicting relationship exists for any author.
Competing interests AV, JM, ARA: none; JvH: Optos (E); DB: Allegro, Apellis, Novartis, Allergan, Genentech, Regeneron, Optos, Santen, Senju, Clearside; MS: Allergan, Regeneron, Novartis, Optos, Spark, Allegro, Appellis, Santen, Clearside, Opthea, Kalvista, Kodiak, Aerie,Greybug; DK, JC: Optos (E); MNG: none; SRS: Allergan (C, F), Carl Zeiss Meditec (C,F), Centervue (C), Genentech (C, F), Heidelberg Engineering (C), Iconic (C), NightstarX (C), Novartis (C), Optos (C,F), Oxurion(C), Topcon (C).
Provenance and peer review Not commissioned; externally peer reviewed.